Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden

Madlaina Costa-Scharplatz, Björn Ställberg, Pankaj Goyal, Yumi Asukai, Jean-Bernard Gruenberger, David Price

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

OBJECTIVES: The objective of this study was to compare the cost effectiveness of once-daily Seebri Breezhaler(®) (glycopyrronium bromide) 50 µg with Spiriva(®) (tiotropium bromide) 18 µg in the maintenance treatment of chronic obstructive pulmonary disease (COPD) in the Swedish setting.

METHODS: A previously published COPD Markov model accounting for disease progression and treatment discontinuation was used. Disease progression included the annual decline in forced expiratory volume in the first second (FEV1) and occurrence of any exacerbations. Efficacy in the model consisted of FEV1 improvement between baseline and 12 weeks and the annual risk ratio of having an exacerbation compared to placebo. These clinical efficacy inputs were derived from a 1-year head-to-head trial comparing glycopyrronium 50 µg to tiotropium 18 µg. Utility values and cost estimates were obtained from the literature. The base-case analysis was performed for a 3-year time horizon. Cost and effects were discounted with 3 % in accordance to Swedish guidelines. Uncertainty was assessed by one-way and probabilistic sensitivity analyses.

RESULTS: Glycopyrronium was found to be less costly and more effective than tiotropium in moderate to severe COPD patients with cost savings of 5197 Swedish kronor (<euro>570, US$725) per patient over a 3-year time horizon. The probabilistic sensitivity analysis indicated that over 99 % of the iterations produced dominant results for glycopyrronium.

CONCLUSION: Glycopyrronium bromide 50 µg once daily can be considered a cost effective alternative to tiotropium bromide 18 µg once daily in the maintenance treatment of COPD patients in Sweden.

Original languageEnglish
Pages (from-to)637-645
Number of pages9
JournalApplied Health Economics and Health Policy
Volume13
Issue number6
Early online date1 Sep 2015
DOIs
Publication statusPublished - Dec 2015

Fingerprint

Glycopyrrolate
Sweden
Chronic Obstructive Pulmonary Disease
Cost-Benefit Analysis
Costs and Cost Analysis
Disease Progression
Cost Savings
Forced Expiratory Volume
Uncertainty
Therapeutics
Odds Ratio
Placebos
Tiotropium Bromide
Cost-effectiveness
Guidelines

Keywords

  • Chronic Obstructive Pulmonary Disease
  • Glycopyrromium Bromide
  • Sweden

Cite this

Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden. / Costa-Scharplatz, Madlaina; Ställberg, Björn; Goyal, Pankaj; Asukai, Yumi; Gruenberger, Jean-Bernard; Price, David.

In: Applied Health Economics and Health Policy, Vol. 13, No. 6, 12.2015, p. 637-645.

Research output: Contribution to journalArticle

Costa-Scharplatz, Madlaina ; Ställberg, Björn ; Goyal, Pankaj ; Asukai, Yumi ; Gruenberger, Jean-Bernard ; Price, David. / Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden. In: Applied Health Economics and Health Policy. 2015 ; Vol. 13, No. 6. pp. 637-645.
@article{209df33219504d27a73c6ec0ad31b0b2,
title = "Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden",
abstract = "OBJECTIVES: The objective of this study was to compare the cost effectiveness of once-daily Seebri Breezhaler({\circledR}) (glycopyrronium bromide) 50 µg with Spiriva({\circledR}) (tiotropium bromide) 18 µg in the maintenance treatment of chronic obstructive pulmonary disease (COPD) in the Swedish setting.METHODS: A previously published COPD Markov model accounting for disease progression and treatment discontinuation was used. Disease progression included the annual decline in forced expiratory volume in the first second (FEV1) and occurrence of any exacerbations. Efficacy in the model consisted of FEV1 improvement between baseline and 12 weeks and the annual risk ratio of having an exacerbation compared to placebo. These clinical efficacy inputs were derived from a 1-year head-to-head trial comparing glycopyrronium 50 µg to tiotropium 18 µg. Utility values and cost estimates were obtained from the literature. The base-case analysis was performed for a 3-year time horizon. Cost and effects were discounted with 3 {\%} in accordance to Swedish guidelines. Uncertainty was assessed by one-way and probabilistic sensitivity analyses.RESULTS: Glycopyrronium was found to be less costly and more effective than tiotropium in moderate to severe COPD patients with cost savings of 5197 Swedish kronor (570, US$725) per patient over a 3-year time horizon. The probabilistic sensitivity analysis indicated that over 99 {\%} of the iterations produced dominant results for glycopyrronium.CONCLUSION: Glycopyrronium bromide 50 µg once daily can be considered a cost effective alternative to tiotropium bromide 18 µg once daily in the maintenance treatment of COPD patients in Sweden.",
keywords = "Chronic Obstructive Pulmonary Disease, Glycopyrromium Bromide, Sweden",
author = "Madlaina Costa-Scharplatz and Bj{\"o}rn St{\"a}llberg and Pankaj Goyal and Yumi Asukai and Jean-Bernard Gruenberger and David Price",
note = "Funding sources: This study was funded by Novartis Pharma AG.",
year = "2015",
month = "12",
doi = "10.1007/s40258-015-0193-2",
language = "English",
volume = "13",
pages = "637--645",
journal = "Applied Health Economics and Health Policy",
issn = "1175-5652",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden

AU - Costa-Scharplatz, Madlaina

AU - Ställberg, Björn

AU - Goyal, Pankaj

AU - Asukai, Yumi

AU - Gruenberger, Jean-Bernard

AU - Price, David

N1 - Funding sources: This study was funded by Novartis Pharma AG.

PY - 2015/12

Y1 - 2015/12

N2 - OBJECTIVES: The objective of this study was to compare the cost effectiveness of once-daily Seebri Breezhaler(®) (glycopyrronium bromide) 50 µg with Spiriva(®) (tiotropium bromide) 18 µg in the maintenance treatment of chronic obstructive pulmonary disease (COPD) in the Swedish setting.METHODS: A previously published COPD Markov model accounting for disease progression and treatment discontinuation was used. Disease progression included the annual decline in forced expiratory volume in the first second (FEV1) and occurrence of any exacerbations. Efficacy in the model consisted of FEV1 improvement between baseline and 12 weeks and the annual risk ratio of having an exacerbation compared to placebo. These clinical efficacy inputs were derived from a 1-year head-to-head trial comparing glycopyrronium 50 µg to tiotropium 18 µg. Utility values and cost estimates were obtained from the literature. The base-case analysis was performed for a 3-year time horizon. Cost and effects were discounted with 3 % in accordance to Swedish guidelines. Uncertainty was assessed by one-way and probabilistic sensitivity analyses.RESULTS: Glycopyrronium was found to be less costly and more effective than tiotropium in moderate to severe COPD patients with cost savings of 5197 Swedish kronor (570, US$725) per patient over a 3-year time horizon. The probabilistic sensitivity analysis indicated that over 99 % of the iterations produced dominant results for glycopyrronium.CONCLUSION: Glycopyrronium bromide 50 µg once daily can be considered a cost effective alternative to tiotropium bromide 18 µg once daily in the maintenance treatment of COPD patients in Sweden.

AB - OBJECTIVES: The objective of this study was to compare the cost effectiveness of once-daily Seebri Breezhaler(®) (glycopyrronium bromide) 50 µg with Spiriva(®) (tiotropium bromide) 18 µg in the maintenance treatment of chronic obstructive pulmonary disease (COPD) in the Swedish setting.METHODS: A previously published COPD Markov model accounting for disease progression and treatment discontinuation was used. Disease progression included the annual decline in forced expiratory volume in the first second (FEV1) and occurrence of any exacerbations. Efficacy in the model consisted of FEV1 improvement between baseline and 12 weeks and the annual risk ratio of having an exacerbation compared to placebo. These clinical efficacy inputs were derived from a 1-year head-to-head trial comparing glycopyrronium 50 µg to tiotropium 18 µg. Utility values and cost estimates were obtained from the literature. The base-case analysis was performed for a 3-year time horizon. Cost and effects were discounted with 3 % in accordance to Swedish guidelines. Uncertainty was assessed by one-way and probabilistic sensitivity analyses.RESULTS: Glycopyrronium was found to be less costly and more effective than tiotropium in moderate to severe COPD patients with cost savings of 5197 Swedish kronor (570, US$725) per patient over a 3-year time horizon. The probabilistic sensitivity analysis indicated that over 99 % of the iterations produced dominant results for glycopyrronium.CONCLUSION: Glycopyrronium bromide 50 µg once daily can be considered a cost effective alternative to tiotropium bromide 18 µg once daily in the maintenance treatment of COPD patients in Sweden.

KW - Chronic Obstructive Pulmonary Disease

KW - Glycopyrromium Bromide

KW - Sweden

U2 - 10.1007/s40258-015-0193-2

DO - 10.1007/s40258-015-0193-2

M3 - Article

VL - 13

SP - 637

EP - 645

JO - Applied Health Economics and Health Policy

JF - Applied Health Economics and Health Policy

SN - 1175-5652

IS - 6

ER -